PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3986.96%
Growth of 3986.96% while AVXL shows flat revenue. Bruce Berkowitz would examine growth quality advantage.
No Data
No Data available this quarter, please select a different quarter.
804.39%
Growth of 804.39% while AVXL shows flat gross profit. Bruce Berkowitz would examine quality advantage.
117.23%
Margin change of 117.23% while AVXL shows flat margins. Bruce Berkowitz would examine quality advantage.
-19.33%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-34.65%
G&A reduction while AVXL shows 6.53% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.37%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-24.37%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.46%
EBITDA growth below 50% of AVXL's 100.00%. Michael Burry would check for structural issues.
98.45%
Margin change of 98.45% while AVXL is flat. Bruce Berkowitz would examine quality.
35.83%
Operating income growth exceeding 1.5x AVXL's 4.31%. David Dodd would verify competitive advantages.
98.43%
Margin change of 98.43% while AVXL is flat. Bruce Berkowitz would examine quality.
-7.89%
Other expenses reduction while AVXL shows 28.87% growth. Joel Greenblatt would examine advantage.
35.97%
Pre-tax income growth exceeding 1.5x AVXL's 6.25%. David Dodd would verify competitive advantages.
98.43%
Margin change of 98.43% while AVXL is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
36.40%
Net income growth exceeding 1.5x AVXL's 7.13%. David Dodd would verify competitive advantages.
98.44%
Margin change of 98.44% while AVXL is flat. Bruce Berkowitz would examine quality.
37.84%
EPS growth exceeding 1.5x AVXL's 6.67%. David Dodd would verify competitive advantages.
37.84%
Diluted EPS growth exceeding 1.5x AVXL's 6.67%. David Dodd would verify competitive advantages.
2.81%
Share count reduction below 50% of AVXL's 0.29%. Michael Burry would check for concerns.
2.81%
Diluted share change of 2.81% while AVXL is stable. Bruce Berkowitz would verify approach.